Loading…
Loading…
A 10% yield sounds like it solves the $6,400 monthly target with far less capital, but two of the three tests that expose a yield trap can disqualify a holding before you ever collect a check.
Agree Realty offers a compelling entry point for long-term income investors at 14x AFFO and a near 5% yield. ADC's robust balance sheet, a credit rating of 'A,' and conservative payout ratio position it well amid higher rates and sector volatility. Despite lowered investment guidance, ADC's acquisition discipline, capital recycling, and record development activity support stable, long-term cash flows.
U.S. markets remained unsettled as cracks emerged in the AI investment boom, while another oil-price surge complicated the inflation outlook ahead of Wednesday's Fed decision. Treasury yields fell for a third straight week as AI-related risk-off flows strengthened, with markets now assigning just 10% odds of an October hike despite still-elevated energy prices. REITs rallied for a third-straight week as earnings opened on an encouraging note: 15 REITs raised full-year FFO guidance, reinforcing the view that fundamentals remain healthier than recent price action.
Generating nearly $100,000 a year in dividend income sounds impossible without a massive nest egg, but the capital you actually need swings wildly depending on where you invest and what risks you are willing to absorb.
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve